Newsletter

Qiagen Receives FDA Approval to Expand Use of EGFR Test for Lung Cancer

Qiagen N.V. (QGEN) announced on January 18 that the company received FDA approval to extend the use of its EGFR test for lung cancer. Qiagen’s therascreen EGFR test is used in conjunction with the targeted therapy GILOTRIF as a first-line treatment for metastatic small cell lung cancer. The FDA approval extends the labeling of the […]

0Comments

Myriad Genetics Receives FDA Approval for Breast Cancer Diagnostic Test

On January 12, Myriad Genetics, Inc. (MYGN) announced that the FDA has approved BRACAnalysis CDx as a companion diagnostic for metastatic breast cancer. Healthcare professionals will be able to use this to identify patients with HER2-negative metastatic breast cancer who have a BRCA mutation and may be candidates for treatment with the PARP inhibitor, Lynparza. […]

0Comments

December 2017 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: December 2017 Scorecard Number of Signals 17 Percent Correct – Prev Close to 5-day Peak 88% Avg Increase – Next Close to 5-day Peak 7% Other stats: Number of signals over $10/share 11 […]

0Comments

La Jolla Pharmaceutical Announces FDA Approval of Giapreza

On December 21, La Jolla Pharmaceutical Company (LJPC) announced that the FDA approved its drug, Giapreza (angiotensin II). The drug can be used to increase blood pressure in adult patients suffering from septic shock or other distributive shock. La Jolla expects to have the drug available for patients in March 2018. Rocket Tickers detected the […]

0Comments

Exelixis Receives FDA Approval for Cabometyx to Treat Renal Cell Carcinoma

On December 19, Exelixis, Inc. (EXEL) announced that the company received additional FDA approval for its drug, Cabometyx. The drug received a label expansion so that it can be used to treat previously untreated advanced renal cell carcinoma. Cabometyx already experienced strong sales in the first nine months of 2017 due to strong demand for […]

0Comments

November 2017 Scorecard

The latest monthly scorecard for the signals generated from Rocket Tickers can be downloaded here. The results are summarized in this table: November 2017 Scorecard Number of Signals 21 Percent Correct – Next Close to 5-day Peak 85.7% Avg Increase – Next Close to 5-day Peak 9.3% Other stats: Number of signals over $10/share 13 […]

0Comments

Catalyst Pharmaceuticals Announces Positive Phase 3 Clinical Trial Results

On November 27, Catalyst Pharmaceutical, Inc. (CPRX) announced positive phase 3 clinical trial results from its drug Firdapse. This was the second phase 3 trial of Firdapse, which shows statistically significant improvement for symptomatic treatment of Lambert-Eaton Myasthenic Syndrome (LEMS). LEMS is a rare autoimmune disorder in which nerves have trouble sending to muscle cells, […]

0Comments

Lannett Announces FDA Acceptance of New Drug Application

On December 1, Lannett Company, Inc. (LCI) announced FDA acceptance of its 505(b)(2) New Drug Application (NDA) for Cocaine Hydrochloride (HCl) Topical Solution. The drug is a proprietary local topical anesthetic with the proposed name Numbrino. The submission is supported by two successful Phase 3 clinical trials.   Rocket Tickers detected the event and sent […]

0Comments

Emergent Biosolutions Receives FDA Approval for Vaccine Production

On November 20, Emergent Biosolutions Inc. (EBS) announced that the company received FDA approval on its supplemental Biologics License Application (sBLA) for the production of the ACAM2000 vaccine. This live vaccine for smallpox will be manufactured in the company’s new live viral manufacturing facility in Canton, Massachusetts. It is the only vaccine approved by the […]

0Comments

Collegium Receives FDA Approval for Xtampza® ER

On November 7, Collegium Pharamceutical, Inc. (COLL) announced FDA approval of its supplemental new drug application for Xtampza® ER. The drug is an abuse-deterrent, extended-release opiod, for severe pain management needing daily, long-term relief. This is an important advance considering the opiod addiction epidemic in the United States. Xtampza® ER is the only single-agent oxycodone with the […]

0Comments

Latest of Knowledge Center